|
Workshop
[In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
Speakers:
Mohan Srinivasan (Loxo/Lilly), Thomas Pillow (Genentech), Bernhard Geierstanger (Firefly Biologics), Laurence Fayadat-Dilman (Merck), Travis Biechele (Shasqi), Judy Hsii (SutroBio), Hui Zhao (Exelixis), Sara Glickstein Bar-Zeev (Genentech), Maya Skubatch (Wilson Sonsini)
Organizers:
Mohan Srinivasan (Loxo Oncology at Lilly), Thomas Pillow (Genentech), Laurence Fayadat-Dilman (Merck)
Date:
2024-03-28
Time:
8:45-17:30 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs: $45; Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(28)Abzena; Altruist Biologics; AsymBio; Aton Biotech; BioAgilytix; Biocytogen Boston Corp; BioIVT; Biomere; BioTether Sciences; Celerion; Cellentia Inc.; ChemPartner Shanghai; Correlia Biosystems Inc; Curia; Discovery Life Sciences; Emery Pharma; Gator Bio; JOINN Biologics Us Inc.; KACTUS; KCAS Bio; Lonza; Meadowhawk Biolabs; Milliporesigma; Mycenax; Nanotemper; newcells biotech; PharmaBlock; Pharmalegacy
Registration: http://www.PBSS.org
Registration deadline:2024-03-27
(it will close sooner if the seating cap is reached)
About the Topic
Sponsored by Resolian, Alturas Analytics, Mycenax
Topics:
- ADC overview
- Target selection
- Chemistry of linker payload & conjugation techniques
- Antibody Engineering for ADCs
- Analytical and Biophysical Characterization of ADCs
- In-vitro and in-vivo activity considerations for ADCs
- CMC Challenges and Opportunities in ADCs
- PK and Toxicology Study Designs
- Clinical Trial Design for ADCs
- Intellectual Property of ADCs
| Time (PST) |
Topic |
Speaker |
| 8:45 am - 8:55 am |
PBSS Welcome Remarks |
Shichang Miao, PhD, PBSS |
| 8:55 am - 9:15 am |
Workshop Overview and ADC overview |
Mohan Srinivasan, PhD, Associate VP, Biologics, Loxo/Lilly |
| 9:15 - 9:35 am |
ADC Target Characterization and Selection Strategies |
Travis Biechele, PhD, VP of Research at Shasqi |
| 9:35 am - 10:20 am |
Chemistry of Linker Payload & Conjugation Techniques |
Thomas Pillow, PhD, Distinguished Scientist, Genentech |
| 10:20 am - 11:05 am |
Antibody Engineering for ADCs |
Bernhard Geierstanger, PhD, Co-Founder and CTO, Firefly Biologics |
| 11:05 am - 11:15 am |
Major Sponsor Presentation |
Resolian |
| 11:15 am - 11:35 am |
Break and Vendor Show |
- |
| 11:35 am - 12:20 pm |
Analytical and Biophysical Characterization of ADCs |
Laurence Fayadat-Dilman, PhD, Executive Director, Discovery Biologics, Merck |
| 12:20 pm - 1:10 pm |
Lunch Break |
Sponsor (Mycenax) |
| 1:10 pm - 1:40 pm |
In-vitro and In-vivo Pharmacology for ADCs |
Travis Biechele, PhD, Senior Principal Scientist, Merck |
| 1:40 pm - 2:25 pm |
CMC Challenges and Opportunities in ADCs |
Judy Hsii, MS, Executive Director, Sutro Biopharma |
| 2:25 pm - 3:10 pm |
PK and Toxicology Study Designs |
Hui Zhao, PhD, Senior Director of Translational Biology, Exelixis |
| 3:10 pm - 3:20 pm |
Major Sponsor Presentation |
Alturas Analytics |
| 3:20 pm - 3:40 pm |
Break and Vendor Show |
- |
| 3:40 pm - 4:20 pm |
Clinical Trial Design for ADCs |
Sara Glickstein Bar-Zeev, PhD, Principal Clinical Scientist, Genentech |
| 4:20 pm - 5:00 pm |
Intellectual Property of ADCs |
Maya Skubatch, JD, Partner at Wilson Sonsini Goodrich & Rosati |
| 5:00 pm - 5:30 pm |
Panel Discussion & Closing Remarks |
All Speakers |
| 5:30 PM - 6:30 pm |
Happy Hour |
Sponsor (Correlia Biosystems) |
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Current State of Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapies
|
2024-12-05, [Free Online] Innovative Mass Spectrometry and Related Technologies for Life Science and Drug Development
|
2024-12-13, Why All These New Modalities?
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Allucent
Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
PharmaResources
Top-tier small molecule CRO/CDMO offering comprehensive supports from Medicinal Chemistry, DMPK, and CMC to GMP manufacturing for commercialization.
|
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
Submit a Text Ad
|